Scarica l'app Stockscreener
2.05
19.88%
0.34
Dopo l'orario di chiusura:
2.06
0.01
+0.49%
Precedente Chiudi:
$1.71
Aprire:
$1.8
Volume 24 ore:
389.50K
Relative Volume:
2.92
Capitalizzazione di mercato:
$26.89M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+28.12%
1M Prestazione:
+95.24%
6M Prestazione:
-55.14%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$1.73
$2.10
Intervallo di 1 settimana:
$1.5298
$2.10
Portata 52W:
$0.69
$9.55
Scienture Holdings Inc Stock (SCNX) Company Profile
Nome
Scienture Holdings Inc
Settore
Industria
Telefono
(800) 261 0281
Indirizzo
2420 BRUNELLO TRACE, LUTZ
Confronta SCNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
2.05 | 20.99M | 0 | 0 | 0 | 0.00 |
|
WBA
Walgreens Boots Alliance Inc
|
11.52 | 10.02B | 151.95B | -5.78B | 571.00M | -6.69 |
|
HITI
High Tide Inc
|
2.43 | 189.63M | 376.07M | -22.41M | 18.73M | -0.298 |
|
PETS
Petmed Express Inc
|
3.04 | 70.85M | 270.52M | -6.08M | 17.42M | -0.2944 |
|
WGRX
Wellgistics Health Inc
|
0.8496 | 61.88M | 0 | 0 | 0 | 0.00 |
Scienture Holdings Inc Borsa (SCNX) Ultime notizie
Scienture regains Nasdaq compliance as stock price exceeds $1 - Investing.com
Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements - The Manila Times
Scienture Meets $1 Nasdaq Requirement as FDA-Approved Drug Launch Approaches - Stock Titan
Why Scienture Holdings Inc. stock attracts strong analyst attentionHigh Return Intraday Picks - beatles.ru
How Scienture Holdings Inc. stock performs during market volatilityCapital Doubling Tips - Newser
What makes Scienture Holdings Inc. stock price move sharplyHigh Return Intraday Picks - Newser
Is Scienture Holdings (NASDAQ:SCNX) Using Debt Sensibly? - simplywall.st
Scienture Holdings Secures Indemnification for Leadership - TipRanks
Scienture Holdings terminates equity line of credit ahead of product launch - Investing.com
Scienture Holdings Announces Cancelation of ELOC | SCNX Stock Ne - GuruFocus
Scienture Holdings Announces Cancelation of ELOC - The Manila Times
Scienture Holdings Announces Cancelation of ELOC | SCNX Stock News - GuruFocus
Scienture Holdings, Inc. Terminates Equity Line of Credit to Focus on Launching FDA-Approved Arbli - Nasdaq
Scienture Terminates $310M Credit Line to Focus on Revolutionary Liquid Hypertension Drug Launch - Stock Titan
Scienture appoints Hariharan, Mani as co-CEOs - MSN
SCIENTURE Appoint Dr. Shankar Hariharan and Dr. Narasimhan Mani as Co-CEO’s - citybiz
Scienture Appoints Co-CEOs as Suren Ajjarapu Steps Down - marketscreener.com
SCIENTURE Announces Executive Leadership Transition | SCNX Stock News - GuruFocus
SCIENTURE Announces Executive Leadership Transition - The Manila Times
Scienture Holdings, Inc. Announces Leadership Transition as Suren Ajjarapu Steps Down as CEO and Chairman - Nasdaq
Scienture Names Two Pharma Veterans as Co-CEOs in Strategic Leadership Overhaul - Stock Titan
Scienture’s Leadership Overhaul: A Turnaround Tale for 2025? - AInvest
SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, - GuruFocus
Scienture Holdings, Inc. Announces FDA Patent Listing for Arbli™, First FDA-Approved Liquid Losartan Formulation - Nasdaq
SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL. - The Manila Times
FDA Orange Book Milestone: First-Ever Liquid Losartan Secures Patent Protection Until 2041 - Stock Titan
Long-Term Bull Put Spread Provides Opportunities for ARM Bulls - The Globe and Mail
ON Holding Surges, Leads High-End Retailers Into Reversal - The Globe and Mail
Scienture Holdings: Q1 Earnings Snapshot - CTPost
Scienture Holdings, Inc. SEC 10-Q Report - TradingView
Why Rigetti Computing Stock Soared in April - The Globe and Mail
3 Consumer Discretionary Stocks to Buy in a Divided Economy - The Globe and Mail
Scienture Announces Manufacturing And Supply Chain Readiness For ArbliTM, (Losartan Potassium) Oral Suspension, 10Mg/Ml For A Target Product Launch In July 2025 - marketscreener.com
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. - The Manila Times
SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. | SCNX Stock News - GuruFocus
Revolutionary Liquid Losartan Targets $292M Market: First FDA-Approved Formula Challenges Traditional Tablets - Stock Titan
Scienture Holdings Divests Subsidiaries to Tollo Health - MSN
Scienture Holdings divests subsidiaries for $5 million By Investing.com - Investing.com South Africa
Scienture divests Integra Pharma Solutions, Bonum Health, Softell for $5M - TipRanks
Scienture Sells 3 Subsidiaries to Tollo Health for $5 Million - marketscreener.com
Scienture Announces The Divestiture Of Its Legacy Subsidiaries - MarketScreener
Scienture Holdings divests subsidiaries for $5 million - Investing.com
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - The Manila Times
Strategic Pivot: Scienture Sells Healthcare IT Units for $5M, Doubles Down on Specialty Pharma - Stock Titan
SCNX stock touches 52-week low at $0.97 amid market challenges - Investing.com Canada
Scienture Holdings Files Prospectus Relates To Resale From Time To Time Of Up To 2.6 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
SCNX stock touches 52-week low at $0.97 amid market challenges By Investing.com - Investing.com South Africa
Scienture Holdings gears up for specialty pharma launches - Investing.com
Scienture CEO says focused on execution, growth, expansion for years ahead - TipRanks
Scienture Holdings gears up for specialty pharma launches By Investing.com - Investing.com UK
Scienture Holdings Inc Azioni (SCNX) Dati Finanziari
Non sono disponibili dati finanziari per Scienture Holdings Inc (SCNX). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.47%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):